BRIEF published on 06/28/2024 at 07:05, 1 year 11 months ago GeNeuro announces the results of the GNC-501 trial in post-Covid-19 syndrome Business Strategy Clinical Test GeNeuro Temelimab Post-Covid-19 Syndrome
PRESS RELEASE published on 06/28/2024 at 07:00, 1 year 11 months ago Inside Information / Other news releases GeNeuro announces results of the GNC-501 study addressing post-COVID-19 neuropsychiatric syndromes. Initial findings show no significant improvement with temelimab treatment compared to placebo GeNeuro Temelimab Neuropsychiatric Post-Covid-19 Syndrome GNC-501 Study
BRIEF published on 06/14/2024 at 18:35, 1 year 11 months ago GeNeuro Announces Unanimous Approval of Resolutions at AGM Shareholders Biopharmaceutical AGM Resolutions GeNeuro
PRESS RELEASE published on 06/14/2024 at 18:30, 1 year 11 months ago Inside Information / Other news releases GeNeuro shareholders approve all resolutions proposed at 2024 AGM, including annual report, re-election of Board members, and compensation approval. 81.54% share capital represented at the meeting Shareholders Compensation AGM Resolutions GeNeuro
BRIEF published on 05/29/2024 at 19:32, 2 years ago GeNeuro: Information on the General Meeting of June 12, 2024 Shareholders Biopharmaceutical Multiple Sclerosis General Assembly GeNeuro
PRESS RELEASE published on 05/29/2024 at 19:27, 2 years ago Inside Information / Other news releases GeNeuro announces availability of documents for the annual shareholders’ meeting on June 12, 2024 in Geneva, Switzerland. Documents accessible online and at company headquarters Shareholders' Meeting Annual Meeting GeNeuro Geneva Documents Availability
BRIEF published on 04/30/2024 at 19:59, 2 years 1 month ago GeNeuro presents its 2023 annual results and progresses in its research programs Financial Results Long Covid Medical Research Health GeNeuro SA
PRESS RELEASE published on 04/30/2024 at 19:54, 2 years 1 month ago Inside Information / News release on accounts, results GeNeuro reports 2023 full-year results and provides corporate update including completion of Phase 2 trial for temelimab against post-COVID neuropsychiatric syndromes. Financial visibility extended to Q3 2024 Full-year Results Phase 2 Trial GeNeuro Temelimab Post-COVID
Published on 06/03/2026 at 09:01, 32 minutes ago Apex Announces Drill Program Expansion and H2 Exploration Plans at the Rift Rare Earth Project
Published on 06/03/2026 at 04:58, 4 hours 35 minutes ago Snipp Interactive Reports Q1 2026 Financial Results; Bookings Backlog Reaches Record $20.6 Million; Announces Conference Call on Wednesday, June 3, 2026
Published on 06/03/2026 at 00:00, 9 hours 33 minutes ago Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Published on 06/02/2026 at 22:30, 11 hours 3 minutes ago INEO Announces Effective Date of Share Consolidation
Published on 06/03/2026 at 09:27, 6 minutes ago Bajaj Mobility AG for its 100% subsidiary KTM AG: Senior Executive to strengthen R&D - Christof Lischka appointed Chief Technology and Product Officer of KTM AG
Published on 06/03/2026 at 09:18, 15 minutes ago Homann Holzwerkstoffe publishes its 2025 Sustainability Statement and is already using the revised ESRS
Published on 06/03/2026 at 09:05, 28 minutes ago Dstny Launches Always-On Communications: Business Communications That Never Sleep
Published on 06/03/2026 at 09:00, 33 minutes ago Original-Research: LION E-Mobility AG (von NuWays AG): BUY
Published on 06/03/2026 at 08:45, 48 minutes ago Air Liquide announces milestone investment in South Korea to support SK hynix’s advanced AI memory chip project
Published on 06/02/2026 at 18:03, 15 hours 30 minutes ago Total number of voting rights and shares making up the share capital at May 31, 2026
Published on 06/02/2026 at 17:42, 15 hours 51 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 May 2026
Published on 06/02/2026 at 17:40, 15 hours 53 minutes ago Campus AI enters the implementation phase: Eiffage selected for deployment of shared infrastructure on the Fouju Campus in a deal worth over €120 million
Published on 06/02/2026 at 08:00, 1 day 1 hour ago EURAZEO’S PRIVATE DEBT FUND CLOSES AT RECORD €3.9 BILLION, EXCEEDING ITS INITIAL TARGET
